May 4, 2022
Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase...
Apr 28, 2022
Quanterix’s ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS) has been granted a breakthrough device designation by U.S. regulators. It is thought that the test, which employs the company’s Simoa technology,...
Apr 25, 2022
Drug targeting Epstein-Barr virus shows promise Researchers are investigating the effects of a drug that targets the Epstein-Barr virus in people with multiple sclerosis (MS) in an ongoing phase 1 clinical trial. The drug improves MS symptoms and may even reverse the...
Apr 23, 2022
Hot weather is on its way! But we have good news! At the MS Alliance support group meeting Tuesday, April 12, our guest speakers Marcia Harris and Debra Forman, from MSF, shared information about their many programs and services for people with MS including their...
Apr 11, 2022
Watch your email for upcoming surveys coming your way. Dr. Kidd, at the MS Center, wants to hear directly from people living with MS to better understand why or why not those with MS take Disease-Modifying Treatments (DMTs). Whether you take or do not take a DMT or...
Apr 8, 2022
Symptoms of Sjögren’s syndrome, including dry eyes and mouth, were observed among 16 people with multiple sclerosis (MS), three of whom met the diagnostic criteria for Sjögren’s in a recent study. Given this low number, however, it’s unclear if there is a true...
